A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers.

Summary: Imagine your body has a broken switch that tells cancer cells to grow and spread. Doctors tried giving medicine to turn off one part of the switch, but the cancer was smart and found a workaround. So, researchers decided to test a new combination of two drugs to block both pathways at the exact same time.

In this early study, 25 patients with advanced cancer took the two drugs together. The main goal was to see if the combination was safe and to find the best dose. The good news is that the drugs were safe to take together, and the side effects were exactly what doctors expected. While it didn't cure the cancer, it kept the disease from getting worse in about a third of the patients. Now, doctors know the perfect dose to use in future tests to help fight cancer!